Stifel Nicolaus Maintains Buy on Amgen

Stifel Nicolaus is out with its report today on Amgen AMGN, maintaining Buy. In its report, Stifel Nicolaus writes, "To value Amgen we relied upon a DCF analysis, using our updated bottom-up, market-based model and its related adjusted EBIT, resulting in our one-year target price of $67. We continue to view Amgen's valuation as attractive and maintain our Buy rating." At the time of posting, shares of AMGN were trading pre-market at $55.00, up 0.55% from Friday's close.